BidaskClub cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a report released on Tuesday, January 9th.
Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Kura Oncology from a hold rating to a buy rating and set a $17.00 target price for the company in a research report on Monday, October 2nd. ValuEngine lowered Kura Oncology from a hold rating to a sell rating in a research report on Friday, December 1st. Wedbush assumed coverage on Kura Oncology in a research report on Tuesday, December 26th. They set a buy rating and a $19.00 price objective for the company. Oppenheimer set a $18.00 target price on Kura Oncology and gave the company a buy rating in a research note on Thursday, November 16th. Finally, Cann reaffirmed a buy rating and set a $17.50 target price on shares of Kura Oncology in a research note on Monday, December 11th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Kura Oncology has a consensus rating of Buy and a consensus target price of $18.08.
Kura Oncology (KURA) opened at $19.80 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48. Kura Oncology has a twelve month low of $5.90 and a twelve month high of $21.00.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). analysts predict that Kura Oncology will post -1.52 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of KURA. Schwab Charles Investment Management Inc. acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $226,000. Rhumbline Advisers acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $131,000. State of Wisconsin Investment Board acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $102,000. Bank of New York Mellon Corp acquired a new position in Kura Oncology in the 2nd quarter valued at approximately $291,000. Finally, Teachers Advisors LLC acquired a new position in Kura Oncology in the 2nd quarter valued at approximately $256,000. 62.96% of the stock is owned by institutional investors and hedge funds.
WARNING: “Kura Oncology (NASDAQ:KURA) Lowered to “Sell” at BidaskClub” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/05/bidaskclub-lowers-kura-oncology-kura-to-sell.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.